医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Kyowa Kirin Asia Pacific Announces Establishment of Subsidiary in Australia

2019年03月18日 PM03:30
このエントリーをはてなブックマークに追加


 

TOKYO

Kyowa Kirin Asia Pacific Pte. Ltd. (President: Chikakuni Kotani, Kyowa Kirin Asia Pacific), a wholly owned subsidiary of Kyowa Hakko Kirin Co., Ltd. (President & COO: Masashi Miyamoto, Kyowa Hakko Kirin), announces it has established an Australian subsidiary, named Kyowa Kirin Australia Pty Ltd (Kyowa Kirin Australia). With the establishment of Kyowa Kirin Australia, Kyowa Kirin Asia Pacific aims to launch Kyowa Hakko Kirin’s global strategic products in the country.

“It is our pleasure to announce we have incorporated our subsidiary in Australia,” said Chikakuni Kotani, President of Kyowa Kirin Asia Pacific. “It was announced last month that Kyowa Kirin Group will be shifting to a new global management structure under the “One Kyowa Kirin” policy. Kyowa Kirin Group will be organized into four regions: North America, EMEA, Asia Pacific and Japan, and business expansion will be accelerated globally. This is Kyowa Kirin Asia Pacific’s first entry into Oceania and we are excited about the future possibilities. We believe Kyowa Kirin Australia will contribute to the health and well-being of patients and families in Australia.”

Overview of the Establishment

Company Name   Kyowa Kirin Australia Pty Ltd
Established February 27, 2019
Location Sydney (planned)
General Manager To be decided
Paid-in Capital 5,000,000 AUD
Shareholders Kyowa Kirin Asia Pacific Pte. Ltd. 100%

Description of
business

  Sale of pharmaceutical products in Australia
 

The Kyowa Hakko Kirin Group companies strive to contribute to the health and well-being of people around the world by creating new value through the pursuit of advances in life sciences and technologies.

About Kyowa Kirin
Kyowa Hakko Kirin is a research-based life sciences company, with special strengths in biotechnologies. In the core therapeutic areas of oncology, nephrology and immunology/allergy, Kyowa Hakko Kirin leverages leading-edge biotechnologies centered on antibody technologies, to continually discover innovative new drugs and to develop and market those drugs world-wide. In this way, the company is working to realize its vision of becoming a Japan-based global specialty pharmaceutical company that contributes to the health and wellbeing of people around the world.
Kyowa Kirin Asia Pacific is a wholly owned subsidiary of Kyowa Hakko Kirin, located in Singapore.

You can learn more about the business at: www.kyowa-kirin.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190317005029/en/

CONTACT

Kyowa Hakko Kirin Co. Ltd.
Media
Hiroki Nakamura
+81-3-5205-7205
Email:
media@kyowa-kirin.co.jp

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Eyenuk、糖尿病網膜症スクリーニング用のEyeArt自律的AIシステムに対するFDA認可の取得を発表
  • Eyenuk宣布FDA核准EyeArt自主AI系统用于糖尿病视网膜病变筛查
  • Dr. Reddy’s Laboratories announces the First-to-Market launch of the generic version of Ciprodex® (ciprofloxacin 0.3% and dexamethasone 0.1%) Otic Suspension, USP in the U.S. Market
  • 五款麒麟专利Plasma乳酸菌产品注册为“机能性表示食品”
  • Impella心臓ポンプ、米国食品医薬品局(FDA)からCOVID-19患者の心臓負荷軽減治療に緊急使用許可を取得